News Image

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

By Mill Chart

Last update: May 14, 2024

Here's HALOZYME THERAPEUTICS INC (NASDAQ:HALO) for you, a growth stock our stock screener believes is undervalued. NASDAQ:HALO is scoring impressively in terms of growth while demonstrating strong financials. On top of that, it remains attractively priced. Let's break it down further.

Assessing Growth for NASDAQ:HALO

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:HALO has received a 9 out of 10:

  • The Earnings Per Share has grown by an impressive 39.64% over the past year.
  • Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 45.64% on average per year.
  • Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 22.40%.
  • The Revenue has been growing by 40.42% on average over the past years. This is a very strong growth!
  • Based on estimates for the next years, HALO will show a very strong growth in Earnings Per Share. The EPS will grow by 22.93% on average per year.
  • Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 13.80% on average per year.

Valuation Insights: NASDAQ:HALO

ChartMill provides a Valuation Rating to every stock, ranging from 0 to 10. This rating assesses various valuation aspects, comparing price to earnings and cash flows, while considering factors like profitability and growth. NASDAQ:HALO boasts a 9 out of 10:

  • Compared to the rest of the industry, the Price/Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 97.61% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 28.32, HALO is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 9.37, the valuation of HALO can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, HALO is valued cheaper than 98.80% of the companies in the same industry.
  • HALO is valuated cheaply when we compare the Price/Forward Earnings ratio to 20.24, which is the current average of the S&P500 Index.
  • Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaper than 96.58% of the companies in the same industry.
  • 98.29% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • HALO has a very decent profitability rating, which may justify a higher PE ratio.
  • HALO's earnings are expected to grow with 30.48% in the coming years. This may justify a more expensive valuation.

Exploring NASDAQ:HALO's Health

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NASDAQ:HALO scores a 7 out of 10:

  • An Altman-Z score of 3.76 indicates that HALO is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.76, HALO is in the better half of the industry, outperforming 75.73% of the companies in the same industry.
  • HALO has a debt to FCF ratio of 3.54. This is a good value and a sign of high solvency as HALO would need 3.54 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.54, HALO belongs to the top of the industry, outperforming 95.56% of the companies in the same industry.
  • A Current Ratio of 6.64 indicates that HALO has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.64, HALO is doing good in the industry, outperforming 65.98% of the companies in the same industry.
  • A Quick Ratio of 5.36 indicates that HALO has no problem at all paying its short term obligations.

Understanding NASDAQ:HALO's Profitability

ChartMill employs its own Profitability Rating system for stock evaluation. This score, ranging from 0 to 10, is derived from an analysis of diverse profitability metrics and margins. In the case of NASDAQ:HALO, the assigned 7 is noteworthy for profitability:

  • The Return On Assets of HALO (17.31%) is better than 98.80% of its industry peers.
  • The Return On Equity of HALO (179.30%) is better than 100.00% of its industry peers.
  • HALO's Return On Invested Capital of 18.09% is amongst the best of the industry. HALO outperforms 98.80% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for HALO is above the industry average of 14.45%.
  • The last Return On Invested Capital (18.09%) for HALO is above the 3 year average (17.78%), which is a sign of increasing profitability.
  • HALO has a better Profit Margin (36.95%) than 99.49% of its industry peers.
  • With an excellent Operating Margin value of 44.25%, HALO belongs to the best of the industry, outperforming 99.49% of the companies in the same industry.
  • With an excellent Gross Margin value of 78.51%, HALO belongs to the best of the industry, outperforming 86.50% of the companies in the same industry.

Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of HALO

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (5/29/2024, 7:08:09 PM)

After market: 41.8 -0.96 (-2.25%)

42.76

-0.32 (-0.74%)

HALO News

News Imagea day ago - ChartmillNASDAQ:HALO is probably undervalued for the fundamentals it is displaying.

In a market where value is scarce, HALOZYME THERAPEUTICS INC (NASDAQ:HALO) offers a refreshing opportunity with its solid fundamentals.

News Image9 days ago - Halozyme Therapeutics, Inc.Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb was reassigned a Prescription Drug User Fee...

News Image13 days ago - Market News VideoHALO July 19th Options Begin Trading
News Image14 days ago - Investor's Business DailyHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating

On Thursday, biotech Halozyme Therapeutics stock had its Relative Strength (RS) Rating upgraded to 84, up from 80 a day earlier.

News Image16 days ago - Investor's Business DailyCatalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating

On Tuesday, Catalyst Pharmaceuticals stock hit a key technical milestone, with its Relative Strength Rating climbing to 83 from 79.

News Image16 days ago - ChartmillWhile growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.

Investors seeking growth at a reasonable cost should explore NASDAQ:HALO.

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the...

News Image21 days ago - USA News GroupBiotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/PRNewswire/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of...

News Image21 days ago - InvestorPlaceThe 3 Best Biotech Stocks to Buy in May 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

News Image22 days ago - Halozyme Therapeutics, Inc.Halozyme to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present...

News Image22 days ago - InvestorPlaceHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

HALO stock results show that Halozyme Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

News Image22 days ago - BusinessInsiderHALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Halozyme Therapeutics (NASDAQ:HALO) just reported results for the first quarter...

HALO Links
Follow us for more